CDXS — Codexis Inc
NASDAQ · Healthcare · Biotechnology
$1.50
-$0.01 (-0.33%)
Codexis Inc (CDXS) is a biotechnology company listed on NASDAQ. It is led by Stephen George Dilly MBBS, Ph.D., based in 200 Penobscot Drive, Redwood City, CA, United States, 94063, with about 188 employees. Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Latest reported CDXS revenue for 2025-09-30 was $8.6M. Net income was -$19.6M. Revenue was down 43.9% from 2025-06-30 to 2025-09-30. CDXS currently screens at market cap $257.6M.
Use this CDXS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CDXS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CDXS SEC filings page. Lician reads the product cache first so this HTML stays unique to Codexis Inc even when a live quote feed is slow.
About Codexis Inc
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
CDXS Key Statistics
Market Cap
$257.65M
Volume
335,023
Previous Close
$1.65
Day Range
$1.60 – $1.65
EPS
-$0.89
Revenue
$59.34M
Net Income
-$65.28M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-15.4%
Profit Margin
-110.0%
Employees
188
CDXS Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $59.34M | $70.14M | $138.59M | $104.75M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$65.28M | -$76.24M | -$33.59M | -$21.28M |
| EPS (Diluted) | -$0.89 | -$1.12 | -$0.51 | -$0.33 |
Total Assets
$149.01M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$19.26M
Operating Cash Flow
-$49.41M
Free Cash Flow
$0.00
Codexis Inc Company Information
- President, CEO & Chairman
- Stephen George Dilly MBBS, Ph.D.
- Headquarters
- 200 Penobscot Drive, Redwood City, CA, United States, 94063
- Website
- www.codexis.com
- Phone
- 650 421 8100
- IPO / Founded
- 2010-04-22
- Sector
- Healthcare
- Industry
- Biotechnology